HRP20090627T1 - Inhibitori hcv ns3 proteaze - Google Patents
Inhibitori hcv ns3 proteaze Download PDFInfo
- Publication number
- HRP20090627T1 HRP20090627T1 HR20090627T HRP20090627T HRP20090627T1 HR P20090627 T1 HRP20090627 T1 HR P20090627T1 HR 20090627 T HR20090627 T HR 20090627T HR P20090627 T HRP20090627 T HR P20090627T HR P20090627 T1 HRP20090627 T1 HR P20090627T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- hydrate
- acceptable salt
- image
- hcv
- Prior art date
Links
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 2
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 2
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 2
- 239000003443 antiviral agent Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 229940122604 HCV protease inhibitor Drugs 0.000 claims 2
- 229940124772 HCV-NS5B polymerase inhibitor Drugs 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70076405P | 2005-07-20 | 2005-07-20 | |
US72456605P | 2005-10-07 | 2005-10-07 | |
PCT/US2006/027573 WO2007015787A1 (en) | 2005-07-20 | 2006-07-14 | Hcv ns3 protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20090627T1 true HRP20090627T1 (hr) | 2010-01-31 |
Family
ID=37467463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090627T HRP20090627T1 (hr) | 2005-07-20 | 2009-11-24 | Inhibitori hcv ns3 proteaze |
Country Status (38)
Country | Link |
---|---|
US (2) | US7470664B2 (ko) |
EP (2) | EP1924593B9 (ko) |
JP (2) | JP4621282B2 (ko) |
KR (1) | KR101296095B1 (ko) |
AR (1) | AR057456A1 (ko) |
AT (1) | ATE443075T1 (ko) |
AU (1) | AU2006276189B9 (ko) |
BR (1) | BRPI0613633A2 (ko) |
CA (1) | CA2615022C (ko) |
CR (1) | CR9621A (ko) |
CY (1) | CY1109671T1 (ko) |
DE (1) | DE602006009280D1 (ko) |
DK (1) | DK1924593T3 (ko) |
DO (2) | DOP2006000171A (ko) |
EA (1) | EA013331B1 (ko) |
EC (1) | ECSP088107A (ko) |
ES (2) | ES2332821T3 (ko) |
GE (1) | GEP20115248B (ko) |
GT (1) | GT200600317A (ko) |
HK (1) | HK1121169A1 (ko) |
HN (1) | HN2008000087A (ko) |
HR (1) | HRP20090627T1 (ko) |
IL (1) | IL188618A0 (ko) |
JO (1) | JO2593B1 (ko) |
MA (1) | MA30198B1 (ko) |
MX (1) | MX2008000866A (ko) |
MY (1) | MY142240A (ko) |
NO (1) | NO20080879L (ko) |
NZ (1) | NZ565223A (ko) |
PE (1) | PE20070364A1 (ko) |
PL (1) | PL1924593T3 (ko) |
PT (1) | PT1924593E (ko) |
RS (1) | RS51101B (ko) |
SG (1) | SG164376A1 (ko) |
SI (1) | SI1924593T1 (ko) |
TN (1) | TNSN08033A1 (ko) |
TW (1) | TWI387603B (ko) |
WO (2) | WO2007015787A1 (ko) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
WO2006119061A2 (en) * | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
KR101269568B1 (ko) * | 2005-07-04 | 2013-06-04 | 자난 사이텍 컴퍼니 리미티드 | 루테늄 착물 리간드, 루테늄 착물, 고정 루테늄 착물 촉매및 그의 제조방법과 용도 |
TWI387603B (zh) * | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
WO2007015824A2 (en) * | 2005-07-25 | 2007-02-08 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
RU2008107972A (ru) * | 2005-08-01 | 2009-09-10 | Мерк энд Ко., Инк. (US) | Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv |
WO2007044893A2 (en) | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8138164B2 (en) * | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8309540B2 (en) * | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
AU2007309546A1 (en) * | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
WO2008057209A1 (en) * | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
WO2008057208A2 (en) * | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0625345D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
AU2007335962B2 (en) * | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20100143886A1 (en) | 2007-03-09 | 2010-06-10 | Ludmerer Steven W | In vivo hcv resistance to anti-viral inhibitors |
ATE490961T1 (de) * | 2007-04-24 | 2010-12-15 | Hoffmann La Roche | Verfahren für hcv-proteasehemmerzwischenprodukt |
BRPI0811020A2 (pt) * | 2007-05-03 | 2015-07-21 | Intermune Inc | Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral. |
CA2686546A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
CA2693537C (en) * | 2007-07-17 | 2013-06-25 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
CA2699891C (en) * | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
US8383583B2 (en) * | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
US8304385B2 (en) | 2007-11-14 | 2012-11-06 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors |
EP2224801A4 (en) | 2007-12-14 | 2011-09-28 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF THE OXIMYL TYPE OF HEPATITIS C VIRUS SERINE PROTEASE |
US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2009085978A1 (en) | 2007-12-20 | 2009-07-09 | Enanta Pharceuticals, Inc. | Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors |
KR20150117305A (ko) * | 2007-12-21 | 2015-10-19 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Hcv 프로테아제 억제제 및 이의 용도 |
US8293705B2 (en) * | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
KR20100131970A (ko) * | 2007-12-21 | 2010-12-16 | 아빌라 테라퓨틱스, 인크. | Hcv 프로테아제 억제제 및 이의 용도 |
AU2015224437B2 (en) * | 2007-12-21 | 2017-05-25 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
NZ587133A (en) | 2008-02-04 | 2012-10-26 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitor compounds for treating an HCV infection |
EP2268285B1 (en) * | 2008-02-25 | 2018-06-27 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
JP5490778B2 (ja) * | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
MX2010011306A (es) * | 2008-04-15 | 2010-11-09 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8461107B2 (en) * | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
DK2540350T3 (da) * | 2008-07-22 | 2014-08-04 | Merck Sharp & Dohme | Kombinationer af en makrocyklisk quinoxalinforbindelse, hvilken er enhcv-ns3-protease-inhibitor med andre hcv-midler |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2012512878A (ja) | 2008-12-19 | 2012-06-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hcvns3プロテアーゼインヒビター |
MX2011007195A (es) | 2009-01-07 | 2013-07-12 | Scynexis Inc | Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih). |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
CA2758072A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
CA2761650C (en) | 2009-05-13 | 2015-05-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
WO2010135748A1 (en) * | 2009-05-22 | 2010-11-25 | Sequoia Pharmaceuticals Inc. | Bimacrocyclic hcv ns3 protease inhibitors |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
EP2470189A4 (en) * | 2009-08-27 | 2013-01-23 | Merck Sharp & Dohme | METHODS FOR PREPARING HEPATITIS C VIRUS PROTEASE INHIBITORS |
US20110081315A1 (en) * | 2009-09-28 | 2011-04-07 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
WO2011049908A2 (en) | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
JP5833022B2 (ja) | 2010-01-27 | 2015-12-16 | エービー・ファーマ・リミテッド | C型肝炎ウィルス阻害剤としてのポリ複素環式化合物 |
CN103096891A (zh) | 2010-06-24 | 2013-05-08 | 判米德有限公司 | 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病 |
CA2812261C (en) | 2010-09-21 | 2017-02-21 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived hcv serine protease inhibitors |
US8729014B2 (en) | 2010-11-01 | 2014-05-20 | Rfs Pharma, Llc | Specific HCV NS3 protease inhibitors |
JP6034802B2 (ja) * | 2010-12-14 | 2016-11-30 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 大環状ラクタムの調製のための方法および中間体 |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2857705A1 (en) * | 2011-06-16 | 2012-12-20 | AB Pharma Ltd. | Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof |
US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
CN103889439A (zh) | 2011-08-19 | 2014-06-25 | 默沙东公司 | Hcv蛋白酶抑制剂的晶体形式 |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
CN104220067A (zh) * | 2011-10-31 | 2014-12-17 | 默沙东公司 | 可用于治疗病毒性疾病的组合物 |
WO2013106631A1 (en) * | 2012-01-11 | 2013-07-18 | Abbvie Inc. | Processes for making hcv protease inhibitors |
CN104039774A (zh) | 2012-01-12 | 2014-09-10 | Rfs制药公司 | Hcv ns3蛋白酶抑制剂 |
CN102617705B (zh) | 2012-02-16 | 2014-12-31 | 上海纬诺医药科技有限公司 | 抑制丙肝病毒复制的大环类化合物 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
TW201408669A (zh) * | 2012-08-08 | 2014-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
EA029088B1 (ru) | 2013-03-15 | 2018-02-28 | Джилид Сайэнс, Инк. | Макроциклические и бициклические ингибиторы вируса гепатита c |
US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
EP2970344A2 (en) * | 2013-03-15 | 2016-01-20 | Cerenis Therapeutics Holding SA | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
CN105636923A (zh) | 2013-10-18 | 2016-06-01 | 默沙东公司 | 用于制备大环内酯酰胺的方法和中间体 |
CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
FR2722210B1 (fr) * | 1994-07-08 | 1996-08-14 | Rhone Poulenc Rorer Sa | Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese |
US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
EP1003775B1 (en) | 1997-08-11 | 2005-03-16 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
WO1999007734A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
DK1058686T3 (da) | 1998-02-25 | 2007-03-05 | Univ Emory | 2'-fluornukleosider |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
EP1066247B1 (en) | 1998-03-31 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
EP1106626B1 (en) | 1998-08-10 | 2003-05-28 | Hokkaido Electric Power Company, Incorporated | Process for the preparation of regular glycopeptides |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
PT1196414E (pt) | 1999-06-25 | 2003-12-31 | Vertex Pharma | Pro-farmacos de inibidores carbamato de impdh |
CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
SK11922002A3 (sk) | 2000-02-18 | 2003-06-03 | Shire Biochem Inc. | Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom |
WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
IL151934A0 (en) | 2000-04-05 | 2003-04-10 | Schering Corp | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
DE60136620D1 (de) | 2000-04-13 | 2009-01-02 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CZ301182B6 (cs) | 2000-05-26 | 2009-12-02 | Idenix (Cayman) Limited | Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
WO2002014376A2 (en) | 2000-08-10 | 2002-02-21 | Trustees Of Boston College | Recyclable metathesis catalysts |
US6955174B2 (en) * | 2000-08-18 | 2005-10-18 | Uryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
AU2001282528A1 (en) | 2000-09-01 | 2002-03-22 | Shionogi And Co., Ltd. | Compounds having anti-hepatitis c virus effect |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
MXPA03005219A (es) | 2000-12-12 | 2003-09-25 | Schering Corp | Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c. |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
KR20030081343A (ko) | 2000-12-15 | 2003-10-17 | 파마셋, 리미티드 | 플라비비리다에 감염 치료용 항바이러스제 |
WO2002051425A1 (fr) | 2000-12-26 | 2002-07-04 | Mitsubishi Pharma Corporation | Remedes pour l'hepatite c |
ES2532836T3 (es) | 2001-01-22 | 2015-04-01 | Merck Sharp & Dohme Corp. | Derivados de nucleósidos como inhibidores de la ARN polimerasa viral dependiente de ARN |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
EP1423095B1 (en) | 2001-08-14 | 2016-09-28 | Tel Aviv University Future Technology Development L.P. | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
AU2002330154A1 (en) | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
EP1465862A1 (en) | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
GB0201179D0 (en) | 2002-01-18 | 2002-03-06 | Angeletti P Ist Richerche Bio | Therapeutic agents |
CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US7323453B2 (en) | 2002-02-13 | 2008-01-29 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
WO2003093290A2 (en) | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003269890A1 (en) | 2002-06-21 | 2004-01-06 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
CA2488484A1 (en) | 2002-06-27 | 2004-01-08 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
ES2469569T3 (es) | 2002-06-28 | 2014-06-18 | Idenix Pharmaceuticals, Inc. | Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae |
AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CA2490200C (en) | 2002-06-28 | 2012-01-03 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
US20060264389A1 (en) | 2002-07-16 | 2006-11-23 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
CA2492607A1 (en) | 2002-07-25 | 2004-02-05 | Micrologix Biotech Inc. | Anti-viral 7-deaza d-nucleosides and uses thereof |
AU2003257157C1 (en) | 2002-08-01 | 2010-03-18 | Pharmasset Inc. | Compounds with the bicyclo[4.2.1] nonane system for the treatment of Flaviviridae infections |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
JP2007524576A (ja) * | 2003-02-07 | 2007-08-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状のc型肝炎セリンプロテアーゼ阻害剤 |
US20040254159A1 (en) | 2003-02-27 | 2004-12-16 | Hasvold Lisa A. | Heterocyclic kinase inhibitors |
CA2516016C (en) | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
UA81028C2 (en) | 2003-04-02 | 2007-11-26 | Boehringer Ingelheim Int | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
AR044129A1 (es) | 2003-05-06 | 2005-08-24 | Altana Pharma Ag | Compuestos intermedios de imidazopiridina. proceso de preparacion. |
CN103204903A (zh) | 2003-05-21 | 2013-07-17 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
US6955184B2 (en) | 2003-05-29 | 2005-10-18 | Honeywell International, Inc. | Pneumatic generator system for simulating operating conditions of an aircraft |
WO2005000864A1 (en) | 2003-06-19 | 2005-01-06 | F. Hoffmann-La Roche Ag | Processes for preparing 4’azido nucleoside derivatives |
US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
AU2005228894B9 (en) | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
TWI387603B (zh) * | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
GB0519797D0 (en) | 2005-09-29 | 2005-11-09 | Istituto Di Ricerche D Biolog | Therapeutic agents |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
WO2008019303A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors |
WO2008057208A2 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8304385B2 (en) | 2007-11-14 | 2012-11-06 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
-
2006
- 2006-07-12 TW TW095125510A patent/TWI387603B/zh not_active IP Right Cessation
- 2006-07-12 US US11/484,925 patent/US7470664B2/en active Active
- 2006-07-12 AR ARP060102995A patent/AR057456A1/es active IP Right Grant
- 2006-07-14 WO PCT/US2006/027573 patent/WO2007015787A1/en active Application Filing
- 2006-07-14 DE DE602006009280T patent/DE602006009280D1/de active Active
- 2006-07-14 PT PT06787475T patent/PT1924593E/pt unknown
- 2006-07-14 WO PCT/US2006/027831 patent/WO2007015855A1/en active Application Filing
- 2006-07-14 NZ NZ565223A patent/NZ565223A/en not_active IP Right Cessation
- 2006-07-14 DK DK06787475.0T patent/DK1924593T3/da active
- 2006-07-14 JP JP2008522888A patent/JP4621282B2/ja active Active
- 2006-07-14 AT AT06787475T patent/ATE443075T1/de active
- 2006-07-14 EA EA200800371A patent/EA013331B1/ru not_active IP Right Cessation
- 2006-07-14 EP EP06787475A patent/EP1924593B9/en active Active
- 2006-07-14 PL PL06787475T patent/PL1924593T3/pl unknown
- 2006-07-14 ES ES06787475T patent/ES2332821T3/es active Active
- 2006-07-14 MX MX2008000866A patent/MX2008000866A/es active IP Right Grant
- 2006-07-14 RS RSP-2009/0548A patent/RS51101B/sr unknown
- 2006-07-14 CA CA2615022A patent/CA2615022C/en not_active Expired - Fee Related
- 2006-07-14 EP EP06787698.7A patent/EP1910404B9/en not_active Not-in-force
- 2006-07-14 GE GEAP200610513A patent/GEP20115248B/en unknown
- 2006-07-14 AU AU2006276189A patent/AU2006276189B9/en not_active Ceased
- 2006-07-14 ES ES06787698.7T patent/ES2446015T3/es active Active
- 2006-07-14 SG SG201005254-6A patent/SG164376A1/en unknown
- 2006-07-14 KR KR1020087001532A patent/KR101296095B1/ko not_active IP Right Cessation
- 2006-07-14 BR BRPI0613633-8A patent/BRPI0613633A2/pt not_active IP Right Cessation
- 2006-07-14 SI SI200630496T patent/SI1924593T1/sl unknown
- 2006-07-17 JO JO2006229A patent/JO2593B1/en active
- 2006-07-17 GT GT200600317A patent/GT200600317A/es unknown
- 2006-07-18 PE PE2006000864A patent/PE20070364A1/es not_active Application Discontinuation
- 2006-07-19 DO DO2006000171A patent/DOP2006000171A/es unknown
- 2006-07-19 MY MYPI20063431A patent/MY142240A/en unknown
-
2007
- 2007-12-20 CR CR9621A patent/CR9621A/es unknown
-
2008
- 2008-01-06 IL IL188618A patent/IL188618A0/en unknown
- 2008-01-14 EC EC2008008107A patent/ECSP088107A/es unknown
- 2008-01-21 HN HN2008000087A patent/HN2008000087A/es unknown
- 2008-01-21 TN TNP2008000033A patent/TNSN08033A1/en unknown
- 2008-02-18 MA MA30655A patent/MA30198B1/fr unknown
- 2008-02-19 NO NO20080879A patent/NO20080879L/no not_active Application Discontinuation
- 2008-11-20 HK HK08112711.5A patent/HK1121169A1/xx not_active IP Right Cessation
- 2008-12-01 US US12/325,965 patent/US8216999B2/en active Active
-
2009
- 2009-04-27 DO DO2009000094A patent/DOP2009000094A/es unknown
- 2009-11-24 HR HR20090627T patent/HRP20090627T1/hr unknown
- 2009-12-14 CY CY20091101328T patent/CY1109671T1/el unknown
-
2010
- 2010-10-07 JP JP2010227222A patent/JP5345117B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
AR061053A1 (es) | Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
AR034448A1 (es) | Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones | |
BR0114986A (pt) | Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. | |
HRP20220920T1 (hr) | Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom | |
ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
NO20082934L (no) | Antivirale nukleotider | |
RS53588B1 (en) | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | |
HRP20120866T1 (hr) | Makrocikliäśni spojevi hinoksalina kao inhibitori hcv ns3 proteaze | |
MY144718A (en) | Viral polymerase inhibitors. | |
BRPI0509795A (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea | |
SG161315A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
EA201100482A1 (ru) | Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv | |
EA201101492A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
PL1719773T3 (pl) | Skondensowane związki heterotetracykliczne i ich zastosowanie jako inhibitora polimerazy HCV | |
PE20080123A1 (es) | Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c | |
HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
JP2010521483A5 (ko) | ||
AR064319A1 (es) | Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros | |
RU2009102252A (ru) | Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с | |
JP2010508361A5 (ko) | ||
WO2010068760A3 (en) | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |